- Home
- WFRD vs AKRO Comparison
WFRD vs AKRO Comparison
Compare WFRD & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFRD
- AKRO
- Stock Information
- Founded
- WFRD 1941
- AKRO 2017
- Country
- WFRD United States
- AKRO United States
- Employees
- WFRD N/A
- AKRO N/A
- Industry
- WFRD Metal Fabrications
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- WFRD Industrials
- AKRO Health Care
- Exchange
- WFRD Nasdaq
- AKRO Nasdaq
- Market Cap
- WFRD 4.1B
- AKRO 3.7B
- IPO Year
- WFRD N/A
- AKRO 2019
- Fundamental
- Price
- WFRD $71.48
- AKRO $54.00
- Analyst Decision
- WFRD Strong Buy
- AKRO Buy
- Analyst Count
- WFRD 8
- AKRO 10
- Target Price
- WFRD $86.13
- AKRO $73.56
- AVG Volume (30 Days)
- WFRD 930.8K
- AKRO 2.5M
- Earning Date
- WFRD 10-21-2025
- AKRO 11-07-2025
- Dividend Yield
- WFRD 1.40%
- AKRO N/A
- EPS Growth
- WFRD N/A
- AKRO N/A
- EPS
- WFRD 5.52
- AKRO N/A
- Revenue
- WFRD $4,970,000,000.00
- AKRO N/A
- Revenue This Year
- WFRD N/A
- AKRO N/A
- Revenue Next Year
- WFRD N/A
- AKRO N/A
- P/E Ratio
- WFRD $12.90
- AKRO N/A
- Revenue Growth
- WFRD N/A
- AKRO N/A
- 52 Week Low
- WFRD $36.74
- AKRO $21.34
- 52 Week High
- WFRD $91.82
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- WFRD 56.76
- AKRO 67.19
- Support Level
- WFRD $71.09
- AKRO $53.90
- Resistance Level
- WFRD $74.46
- AKRO $54.31
- Average True Range (ATR)
- WFRD 2.81
- AKRO 0.23
- MACD
- WFRD 0.04
- AKRO -0.25
- Stochastic Oscillator
- WFRD 58.96
- AKRO 64.64
About WFRD Weatherford International plc
Weatherford International provides diversified oilfield services across international markets for an array of oilfield types. The firm is a global market leader in artificial lift and tubular running services. Other key product lines include cementing products, directional drilling, and wireline evaluation.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.